1. Home
  2. ENTA vs NEXN Comparison

ENTA vs NEXN Comparison

Compare ENTA & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.51

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

HOLD

Current Price

$6.59

Market Cap

411.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
NEXN
Founded
1995
2007
Country
United States
Israel
Employees
N/A
909
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
411.2M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
NEXN
Price
$12.51
$6.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$20.40
$11.56
AVG Volume (30 Days)
147.1K
341.7K
Earning Date
05-11-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$9.64
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$5.60
52 Week High
$17.15
$12.00

Technical Indicators

Market Signals
Indicator
ENTA
NEXN
Relative Strength Index (RSI) 40.96 42.81
Support Level $12.09 $6.28
Resistance Level $15.52 $6.85
Average True Range (ATR) 0.65 0.35
MACD -0.16 -0.10
Stochastic Oscillator 15.25 16.45

Price Performance

Historical Comparison
ENTA
NEXN

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.

Share on Social Networks: